Monopar Therapeutics Inc. develops clinical and preclinical biopharmaceutical programs for Wilson disease and oncology radiopharmaceuticals. News about MNPR centers on ALXN1840, also described as tiomolibdate choline, a late-stage investigational oral therapy for Wilson disease, including analyses from the Phase 3 FoCus trial, copper-balance data, neurology and hepatology conference presentations, and related peer-reviewed publications.
Company updates also cover the MNPR-101 radiopharmaceutical programs for uPAR-expressing cancers, including MNPR-101-Zr imaging activity, MNPR-101-Lu therapeutic development and IND clearance, and preclinical MNPR-101-Ac work. Recurring corporate themes include financial results, public offerings, balance-sheet updates, and commercial or executive infrastructure as the company advances its pipeline.
Monopar Therapeutics Inc. reported its first-quarter 2024 financial results and a strategic focus on its radiopharma pipeline. The company initiated the MNPR-101-Zr Phase 1 clinical trial and aims to launch the MNPR-101-RIT Phase 1 trial by Q4 2024 or Q1 2025. Monopar is winding down non-radiopharma programs to concentrate resources on radiopharma assets. The company is well-funded till at least June 30, 2025, with a net loss of $1.6 million for Q1 2024. R&D expenses decreased, while G&A expenses saw a slight drop.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.